|Bid||22.87 x 900|
|Ask||22.87 x 1000|
|Day's Range||22.55 - 22.93|
|52 Week Range||18.05 - 31.78|
|Beta (5Y Monthly)||0.26|
|PE Ratio (TTM)||6.29|
|Earnings Date||May 03, 2023 - May 08, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.14|
Subscribe to Yahoo Finance Plus to view Fair Value for VIR
For many investors, the main point of stock picking is to generate higher returns than the overall market. But in any...
SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 15, at 7:15 a.m. PT / 10:15 a.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived the
Vir Biotechnology, Inc. is a biotech company facing the apparent winding down of the Covid crisis while sitting on a huge amount of net cash -- and with other projects in the pipeline. Vir uses this information to develop way of treating infectious diseases. This small biotech has one approved Covid-19 therapy in collaboration with GlaxoSmithKline (with significantly declining revenue) called sotrovimab and four others in the clinic.